SPY380.36-1.97 -0.52%
DIA309.45-4.53 -1.44%
IXIC13,192.35+72.96 0.56%

BRIEF-AstraZeneca Says Kestrel Phase III Trial For Imfinzi Did Not Meet Primary Endpoint

· 02/05/2021 02:10
BRIEF-AstraZeneca Says Kestrel Phase III Trial For Imfinzi Did Not Meet Primary Endpoint

- AstraZeneca PLC AZN.L:

  • ASTRAZENECA PLC - UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI

  • ASTRAZENECA - KESTREL PHASE III TRIAL FOR ASTRAZENECA'S IMFINZI (DURVALUMAB) DID NOT MEET PRIMARY ENDPOINT OF IMPROVING OVERALL SURVIVAL

  • ASTRAZENECA - SAFETY AND TOLERABILITY PROFILES FOR IMFINZI AS A MONOTHERAPY AND IN COMBINATION WITH TREMELIMUMAB WERE CONSISTENT WITH PREVIOUS TRIALS

  • ASTRAZENECA - COMBINATION OF IMFINZI PLUS TREMELIMUMAB DID NOT INDICATE AN OS BENEFIT IN 'ALL-COMER' PATIENTS, A SECONDARY ENDPOINT.

Source text for Eikon: ID:nRSE1314Oa

Further company coverage: AZN.L


((Reuters.Briefs@thomsonreuters.com;))